Tag: Sun Pharma
Organon acquisition reports speculative – Sun Pharma
Sun Pharmaceutical Industries has called reports of its potential $10 billion acquisition of US-based Organon “speculative,” responding to a clarification request from the BSE....
Sun Pharma’s Q1FY26 results
In the quarter ended June 2025 (Q1FY26), Sun Pharma's stock's consolidated net profit fell 20% to ₹2,279 crore, dented by a one-time exceptional charge....
US exempts Indian pharmaceuticals from reciprocal tariffs
In the recent progression of imposing tariffs, U.S. President Donald Trump has exempted Indian pharmaceutical products from the newly imposed reciprocal tariffs. This exemption...
Sun Pharma to acquire Checkpoint Therapeutics for US$ 355 million
Drug maker Sun Pharma, which is listed on the stock exchange, will acquire Nasdaq-listed Checkpoint Therapeutics, a immunotherapy and targeted oncology company, for $355...
FDA go-ahead to Sun Pharma to develop osteoarthritis knee pain drug
Sun Pharma and Israel-based Moebius Medical have announced that the US Food and Drug Administration (FDA) has granted fast-frack designation (FTD) to MM-II (large...
Sun Pharma to acquire Concert Pharmaceuticals of US
Indian multinational pharmaceutical company Sun Pharmaceutical industries will acquire the US-based Concert Pharmaceuticals for $576 million, the company announced on 19 January 2023.
Sun Pharma...
The Halol unit of Sun Pharma receives 10 observations
Sun Pharmaceutical Industries said that the health regulator of the US issued a Form 483 having 10 observations after the completion of the inspection...
Sun Pharma’s subsidiary takes over Galderma’s companies
Sun Pharma’s share reaches 1.84% to 871.25 on BSE. About US$99.3 million were paid by Taro after considering working capital adjustments. Sun Pharma captured...
US FDA resumes inspections in India
In February 2022, FDA officials stated that the agency is eager to resume inspections, including surprise inspections in India. On Thursday, 10 March 2022,...
Molnupiravir newest antiviral for Covid-19
Molnupiravir, the newest antiviral on the market to treat Covid-19, had been submitted to the Indian drug regulatory authorities for approval. Thirteen were given...